Acenocoumarol

Chemical formula: C₁₉H₁₅NO₆  Molecular mass: 353.326 g/mol  PubChem compound: 54676537

Therapeutic indications

Acenocoumarol is indicated for:

Treatment and prevention of thromboembolic diseases

Population group: only adults (18 years old or older)

Thromboembolic disorder

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Contraindications

Acenocoumarol is contraindicated in the following cases:

Pregnancy

Pregnancy

Patients unable to co-operate

at least one of
Uncooperative behavior
Uncooperative character
Non-compliant character
Alcoholic
Alcoholism
Mental disorder

Surgery on the central nervous system or eyes and traumatising surgery

Surgical procedure

Peptic ulcers or haemorrhage, acute pericarditis, pericardial effusion, infective endocarditis

at least one of
Peptic ulcer
Gastrointestinal hemorrhage
Genitourinary tract hemorrhage
Respiratory tract hemorrhage
Intracranial hemorrhage
Acute pericarditis
Pericardial effusion
Infective endocarditis

Severe hypertension

Hypertension

Severe hepatic impairment

Hepatic failure stage IV

Severe renal disease

at least one of

Renal failure stage 5: Kidney failure (GFR <15 mL/min/1.73 m2 or dialysis)

Increased fibrinolytic activity

Fibrinolytic bleeding syndrome

Haemorrhagic diathesis or haemorrhagic blood dyscrasia

at least one of
Bleeding
At risk of hemorrhage
Blood disease

Get recommendations

Factors such as age, gender, and health history are evaluated to create a personalized medication regimen.

Ask the Reasoner

Related medicines

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.